Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Late news: Corin's Cormet FDA approved, launch in third quarter:

This article was originally published in Clinica

Executive Summary

As Clinica went to press, UK company Corin announced that it had received FDA approval for Cormet, its metal-on-metal (MOM) hip resurfacing device, thus ending Smith & Nephew's US monopoly. The move could see Stryker - Corin's distribution partner for the product - start marketing the device during the third quarter of this year, when it will become a direct competitor of S&N's Birmingham Hip. Code Securities has predicted Cormet sales of $20m in 2007, rising to $36m in 2008, Goldman Sachs has estimated that Stryker and S&N will each control 35-40% of the $400m US hip resurfacing market by 2010. Hip resurfacing is an alternative procedure to hip replacement that allows patients to return to more active lifestyles.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049071

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel